A program to help myeloproliferative neoplasm patients improve their lifestyle
Official title: I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
Run by Massachusetts General Hospital · NCT05842603 · Data updated 2026-11-12
This study is testing a 12-week program that helps people with myeloproliferative neoplasms improve their nutrition and physical activity to see if it can lead to healthier living.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 3 sites (Boston, Massachusetts and 2 other locations) |
| Status | Recruiting |
| Started | March 1, 2024 |
| Main results expected | January 1, 2027 |
| Study ends | January 1, 2027 |
| Registry record updated | September 25, 2025 |
| Trial ID | NCT05842603 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older diagnosed with myeloproliferative neoplasms and having at least one cardiovascular risk factor.
✕Probably not a fit
Patients with intermediate or high-risk myelofibrosis or those without any cardiovascular risk factors may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot study aims to evaluate the feasibility of the Cardiac Lifestyle Program (CLP) for patients diagnosed with myeloproliferative neoplasms (MPNs). Over a 12-week period, participants will engage in tailored nutrition and physical activity interventions designed to promote healthier living. The study will involve screening for eligibility, in-clinic visits, questionnaires, group classes, and blood work to assess the program's effectiveness. Approximately 30 patients will be enrolled to determine if they can successfully complete the program.
Why it matters
Potential benefit: If successful, this program could help improve the health and quality of life for patients with myeloproliferative disorders.
How similar studies have gone: While this approach is novel for myeloproliferative disorder patients, similar lifestyle interventions have shown success in other patient populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: -≥18 years of age * Diagnosed with an MPN by WHO 2016 criteria,22 including essential thrombocythemia (ET), polycythemia vera (PV), prefibrotic myelofibrosis (pre-MF), myelofibrosis (MF), and MPN not otherwise specified (NOS). Within MF patients, only patients who are low or intermediate-1 risk by the Dynamic International Prognostic Scoring System (DIPSS) are eligible.23 All risk groups are eligible for the remaining MPN subtypes. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Must have at least one cardiovascular risk factor including: Body mass index (BMI) \>25 kg/m2, hypertension, hyperlipidemia, diabetes mellitus or pre-diabetes or metabolic syndrome, or any prior history of cardiovascular disease, transient ischemic attack, stroke, or peripheral vascular disease. Patients not meeting any cardiovascular risk criteria must receive prior approval from the PI to participate in this study. Exclusion Criteria: \-- MF patients with intermediate-2 or high-risk disease by DIPSS * ECOG performance status \>2. * Any injury or medical condition that would prohibit being able to safely perform exercise, as determined by the treating physician.
Where it's running
-
Brigham and Women's Hospital
Boston, Massachusetts, United States Recruiting -
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States Recruiting -
Dana-Farber Cancer Institute
Boston, Massachusetts, United States Not yet recruiting
Study contacts
- Principal investigator: Gabriela Hobbs, MD — Massachusetts General Hospital
- Study coordinator: Gabriela Hobbs, MD
- Email: ghobbs@partners.org
- Phone: 617-724-1124
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CIML NK cell therapy to prevent relapse after stem cell transplant
This study is testing if a new type of immune cell therapy can help prevent relapse in people with certain blood cancers after they receive a stem cell transplant.
-
AI-based precision oncology clinical trial matching and registry
This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.
-
Genetics of Blood Cancers in the U.S. population
This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.
-
Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma
Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.
-
Cord blood transplant for children and young adults with blood cancers.
This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.
-
Cohort for people with chronic myelomonocytic leukemia
This project will collect blood and bone marrow samples from adults with chronic myelomonocytic leukemia at diagnosis and during disease changes to create an anonymized biobank researchers can use to test new questions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.